- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03330327
Molar Potency Study of HM12470 in Healthy Subjects
October 31, 2017 updated by: Hanmi Pharmaceutical Company Limited
An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12470 and Regular Human Insulin in Healthy Subjects
This is a phase 1 study to assess and compare molar potency of HM12470 and regular human insulin in healthy subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- Hanmi Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Females must be non-pregnant and non-lactating
- Males must be surgically sterile or using an acceptable contraceptive method
Exclusion Criteria:
- Participation in an investigational study within 30 days prior to dosing
- Use of new prescription and non-prescription drugs within 3 weeks preceding the first dosing
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
Intravenous (IV) infusion of HM12470
|
HM12470 is a long-acting insulin analogue
|
Experimental: Part 2: Sequence 1
Intravenous (IV) infusion of HM12470
|
HM12470 is a long-acting insulin analogue
|
Experimental: Part 2: Sequence 2
Intravenous (IV) infusion of HM12470
|
HM12470 is a long-acting insulin analogue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood glucose assessment of HM12470 and regular human insulin (RHI) over the entire dosing period
Time Frame: 1 month
|
- Comparison of HM12470 to RHI based on blood glucose profile generated by intravenous infusion
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of HM12470
Time Frame: 1 month
|
- Maximum concentration of HM12470 over the entire dosing period
|
1 month
|
AUC of HM12470
Time Frame: 1 month
|
- Area Under the Curve of HM12470 over the entire dosing period
|
1 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2015
Primary Completion (Actual)
August 17, 2017
Study Completion (Actual)
August 17, 2017
Study Registration Dates
First Submitted
October 26, 2017
First Submitted That Met QC Criteria
October 31, 2017
First Posted (Actual)
November 6, 2017
Study Record Updates
Last Update Posted (Actual)
November 6, 2017
Last Update Submitted That Met QC Criteria
October 31, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- HM-INS-115-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on HM12470
-
Hanmi Pharmaceutical Company LimitedCompletedDiabetes MellitusKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States